Lixte Biotechnology
Price & Volume
Stats
See more52W Range | $1.31-$4.40 |
Market Cap | $4.4M |
Shares Short | 136,434 |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | -$1.73 |
News
See moreYahoo Finance • last year
LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer
Yahoo Finance • last year
LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements
Yahoo Finance • 2 years ago
LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma
Yahoo Finance • 2 years ago
LIXTE BIOTECHNOLOGY HOLDINGS REPORTS NEWLY PUBLISHED INDEPENDENT PRE-CLINICAL RESEARCH
About
CEO | Mr. Bastiaan van der Baan M.Sc. |
CFO | Mr. Robert Neal Weingarten |
Address | 680 East Colorado Boulevard, Pasadena, CA, United States, 91101 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 3 |
